Table 4. Factors associated with new onset hormone deficiency in the follow-up period.
| Variable |
n = 225** |
p-value |
|
|---|---|---|---|
| No (n = 199) | Yes (n = 26) | ||
| Age* | 39.78 ± 12.56 | 38.54 ± 13.56 | 0.660β |
| Gender | |||
| Male | 130 (90.28) | 14 (9.72) | 0.251ƿ |
| Female | 69 (85.19) | 12 (14.81) | |
| Previous surgery | |||
| No | 28 (93.33) | 2 (6.67) | 0.364α |
| Yes | 170 (87.63) | 24 (12.37) | |
| Type of surgery | |||
| TS+CONVENTIONAL RADIATION | 1 (100) | 0 (0) | 0.197ƿ |
| TS-TF | 12 (100) | 0 (0) | |
| TS | 146 (87.95) | 20 (12.05) | |
| TF | 11 (73.33) | 4 (26.67) | |
| Tumour size | |||
| Macro | 186 (87.74) | 26 (12.26) | 0.292α |
| Micro | 8 (100) | 0 (0) | |
| Tumour type | |||
| Functioning | 78 (89.66) | 9 (10.34) | 0.652ƿ |
| Non-functioning | 121 (87.68) | 17 (12.32) | |
| Pre CK SRS GTV# | 7,088.63 (4,750.18–11,142.56) | 8,070.82 (4,460.33–13,344.8) | 0.419µ |
| Radiation parameter | |||
| CI# | 1.32 (1.25–1.38) | 1.28 (1.25–1.3) | 0.050µ |
| nCI# | 1.36 (1.3–1.43) | 1.32 (1.28–1.36) | 0.055µ |
| HI* | 1.26 ± 0.05 | 1.25 ± 0.03 | 0.332β |
| C* | 96.82 ± 2.34 | 96.48 ± 2.56 | 0.527β |
*Mean ± SD; #Meadian (IQR); βIndependent t-test; ƿChi-square test; αFischer exact test; µMann Whitney U test
**53 patients lost to endocrine follow-up
p-value of <0.05 was considered significant
TS: Transphenoidal surgery; TF: Transfrontal surgery; CK SRS: CyberKnife stereotactic radiosurgery; GTV: Gross tumour volume;
CI: Conformity index; nCI: New conformity index; HI: Homogeneity index; C: Coverage